BIND Therapeutics Reports First Quarter 2016 Financial Results And Provides Business Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--BIND Therapeutics, Inc. (NASDAQ:BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called ACCURINS®, today reported financial results for the first quarter ended March 31, 2016 and provided a business update.
"Despite our financial challenges, we remain committed to advancing our new R&D strategy of applying our ACCURINS® technology to develop innovative medicines and we have made significant progress during the first quarter,” said Andrew Hirsch, president and chief executive officer at BIND Therapeutics.
"Despite our financial challenges, we remain committed to advancing our new R&D strategy of applying our ACCURINS® technology to develop innovative medicines and we have made significant progress during the first quarter,” said Andrew Hirsch, president and chief executive officer at BIND Therapeutics.